FCPM III SERVICES B.V.
An institutional investment manager in NAARDEN. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2013410.
- Reported value$750.4m
- Positions11
Holdings: 11 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31. The filing's table has 15 lines; lines for the same security and option type are added together here.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 288 | 38.3% | 8,490,353 | Reduced−708,547 | |
| Maplight Therapeutics IncMPLT | COM | 56565P103 | 116 | 15.4% | 3,226,400 | Unchanged | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 85.5 | 11.4% | 3,848,256 | Reduced−796,130 | |
| VOR Biopharma IncVOR | COM NEW | 929033207 | 75.8 | 10.1% | 4,117,354 | Unchanged | |
| Damora Therapeutics Inc | COM NEW | 36322Q206 | 63.5 | 8.5% | 2,441,000 | Unchanged | |
| Replimune Group IncREPL | COM | 76029N106 | 31.1 | 4.1% | 2,808,368 | Unchanged | |
| Crescent Biopharma Inc. | COM | G2545C104 | 30.2 | 4.0% | 1,677,852 | Unchanged | |
| Aura Biosciences IncAURA | COM | 05153U107 | 28.8 | 3.8% | 4,053,775 | New+4,053,775 | |
| Engene Holdings Inc | COM | 29286M105 | 16.7 | 2.2% | 9,632,561 | Unchanged | |
| Bicycle Therapeutics plcBCYC | SPONSORED ADS | 088786108 | 14.7 | 2.0% | 3,468,430 | Unchanged | |
| Engene Holdings Inc | W EXP 10/31/2028 | 29286M113 | 0.8 | 0.1% | 2,878,148 | Unchanged |
Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-350207 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.